Direct HBB Correction Shows Early Sickle Cell Clinical Signal
Kamau Therapeutics disclosed November 4 interim Phase 1/2 RESTORE data for three people with severe sickle cell disease given a revised nula-cel manufacturing process. Two have more than six months of follow-up with predominant…
